Vào đêm trước kỷ nguyên hậu lượng tử: Bitcoin xây dựng thế hệ phòng thủ an ninh tiếp theo như thế nào?

Portola Pharmaceuticals

company

About

Portola Pharmaceuticals develops therapeutics for acute and chronic cardiovascular, and autoimmune and inflammatory diseases.

  • 51 - 100

Details

Last Funding Type
Series C
Last Funding Money Raised
$60.09M
Industries
Biopharma,Biotechnology,Therapeutics
Founded date
Jan 1, 2003
Number Of Employee
51 - 100
Operating Status
Close

Portola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. The company's products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic surgery; for stroke prevention in patients with atrial fibrillation; and for secondary prevention of myocardial infarction and stroke. Its products also include PRT060128, an oral and intravenous ADP receptor antagonist for the treatment of patients with acute coronary syndrome; for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. In addition, the company's products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases and Rheumatoid Arthritis (RA) which is used to treat certain cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Portola Pharmaceuticals, Inc. was founded in 2003 and is based in South San Francisco, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$130.09M
Portola Pharmaceuticals has raised a total of $130.09M in funding over 2 rounds. Their latest funding was raised on Jul 1, 2008 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 1, 2008 Series C $60.09M 1 Detail
May 7, 2007 Series C $70M 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
Portola Pharmaceuticals is funded by 2 investors. Apothecary Capital and CIDC Consultants are the most recent investors.
Investor Name Lead Investor Funding Round
Apothecary Capital Series C
CIDC Consultants Series C